Overview

PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy

Status:
Not yet recruiting

Trial end date:
2022-10-15

Target enrollment:

Participant gender:

Summary

This trial is an open-label, randomized, multicenter study to explore Endostar in combination with standard platinum-based chemotherapy with different methods in patients with advanced/metastatic non-small cell lung cancer (NSCLC)

Phase:

Phase 1

Details

Lead Sponsor:

Jiangsu Simcere Pharmaceutical Co., Ltd.

Treatments:

Endostar protein
Endostatins